Malaria Treatment & Prevention
Plasmodium vivax The other malaria
A good piece in this week's Economist on the "other malaria."
"Numbers are hard to come by, but Ric Price, of Oxford University, reckons that between 80m and 390m people suffer the effects of vivax every year. The cost, to the sufferers alone, is between $1.4 billion and $4 billion a year—and that does not take account of consequential damage to the economies of the countries they live in. These include places like Central Asia and the Caucasus, where falciparum is unknown—for, unlike falciparum, which is genuinely a tropical disease, vivax can thrive in temperate climes. Indeed, in the first half of the 20th century it was found as far north as Archangel, in Russia."
Attached resource:
-
Plasmodium vivax The other malaria (external URL) Link leads to: http://www.economist.com/node/18741412
Summary: A good piece in this week's Economist on the "other malaria."
"Numbers are hard to come by, but Ric Price, of Oxford University, reckons that between 80m and 390m people suffer the effects of vivax every year. The cost, to the sufferers alone, is between $1.4 billion and $4 billion a year—and that does not take account of consequential damage to the economies of the countries they live in. These include places like Central Asia and the Caucasus, where falciparum is unknown—for, unlike falciparum, which is genuinely a tropical disease, vivax can thrive in temperate climes. Indeed, in the first half of the 20th century it was found as far north as Archangel, in Russia."Source: The Economist
Keywords: funding
Edit Comment Text